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Abstract
Purpose—Pharmacy commercial claims databases are widely used for pharmacoepidemiologic
research. However, concerns have been raised that these databases may not fully capture claims
for generic medication as a result of patients filling outside the context of their insurance. This has
implications for many research activities and quality improvement programs. We sought to
estimate the percentage of missing drug claims in US commercial claims data using a novel
design.
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Methods—Using a large US commercial insurance database, we examined the completeness of
warfarin prescription claims among patients with atrial fibrillation receiving regular medical
follow-up and testing to manage warfarin dosing. We examined 14 different 6-month cross
sections. Each cross section was treated independently to identify patients with at least 2
outpatient diagnoses of atrial fibrillation, 2 international normalized ratio tests, and 1 pharmacy
claim. Trends in the percentage of patients with prescription claims for generic and branded
warfarin were compared by year and 6-month periods using chi-square tests and generalized linear
models adjusting for patient characteristics.
Results—Out of 111,170 patients, the percentage of patients with any warfarin drug decreased
slightly from 91.7% (95% CI: 91.0, 92.4) in early 2003 to 87.1% (95% CI: 86.7-87.6) in late 2009
(χ2=93.8, p<0.0001). Over the same interval, the proportion of patients with generic warfarin
exposure appearing increased significantly, while the proportion of patients with branded warfarin
exposure decreased significantly.
Conclusions—Our study supports the possibility that some prescriptions may not be captured in
US commercial insurance databases.
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INTRODUCTION
Pharmacy claims databases are widely used in the United States to study drug safety and
effectiveness, inappropriate medication use, medication adherence, health care disparities,
clinical guideline adherence, and the effects of policy changes.1,2 While patients may be
prescribed medications and not fill them, pharmacy claims are generally thought to be a
good measure of actual drug exposure.3-5 However, it is possible that prescription
medications being used by a patient may not be captured in claims databases.6
This loss of information could happen for various reasons. For example, patients could be
paying out-of-pocket for inexpensive prescriptions, receiving samples from a physician,
obtaining prescriptions through a spouse's pharmacy benefit or other dual pharmacy benefit
such as through Veterans Affairs coverage, or receiving them via mail order from outside
the US.7,8 Concerns have also been raised that very low-cost generic prescription drug
programs may not be reporting pharmacy claims back to the insurer. Low-cost generic
programs started to appear in in the United States beginning in late 20069,10 and are now
currently offered by most chain pharmacies.11-13 Because the cost of the generic
medications may be less than patients’ co-payments in some situations6, patients may
choose to pay in cash without providing insurance information to the pharmacist. If this
occurs, the transaction would not be processed by the pharmacy benefit manager, and a
record of the prescription fill would not appear in the insurance pharmacy claims database.9
Widespread missing prescription claims, leading to misclassification of prescription drug
exposure1, would have important implications for many of research activities.1,14-17 Despite
the importance of this topic, the completeness of pharmacy claims data in US insurance
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databases has not been studied. We examined this issue directly by examining claims for
warfarin among patients with atrial fibrillation who were receiving regular medical follow-
up and testing explicitly to manage warfarin dosing.
METHODS
Warfarin is an anticoagulant that is often used chronically to prevent stroke in patients with
atrial fibrillation. Patients taking warfarin need to be regularly monitored with international
normalized ratio (INR) tests and have doses adjusted accordingly. In patients with atrial
fibrillation, there is little reason that INRs would be regularly ordered on patients without
concomitant warfarin use.18-20 In addition, given that these medications have a narrow
therapeutic index, patients largely remain on one formulation once being initiated,
minimizing the potential for missing claims in this population. Thus, there is limited
potential for frequent switching between brand and generic formulations.20 Few therapeutic
alternatives were also available at the time of study, as newer anticoagulants (e.g.,
dabigatran) were not available until late 2010.19 Using data from a large population of
commercially-insured patients, we examined time trends in warfarin filling among patients
with atrial fibrillation who were receiving regular INR tests.
Study Population and Data
The data for our study came from the TruvenHealth MarketScan Commercial Claims and
Encounters Research Database for the years 2003-2009. These databases include de-
identified patient-specific medical inpatient and outpatient claims, outpatient pharmaceutical
data and enrollment data for approximately 20 million people annually from over 100
nationwide insurers.
We constructed 14 different 6-month non-overlapping cross-sectional cohorts, beginning
from January-June 2003 through July-December 2009, hereafter referred to as early 2003
and late 2009, respectively. Within each 6-month cross section, we selected a cohort of
patients with at least 2 International Classification of Diseases, 9th edition (ICD-9) codes for
atrial fibrillation (AF) (ICD-9: 427.31) occurring on separate days, 2 Current Procedural
Terminology (CPT) codes for an INR (CPT: 85610, 99363, or 99364) occurring on separate
days and with continuous enrollment for the 6-month cross sections. We required the 2
ICD-9 and CPT codes to occur on separate days to ensure that the diagnoses and procedures
were not being used to rule-out a particular condition. INR claims could have occurred at
any point in the 6-month window, which allowed for prevalent use to be captured and for a
conservative design. To ensure patients were using pharmacy benefits, we further restricted
this cohort to individuals with at least 1 prescription fill for any medication during the 6-
month cross section.
To eliminate potential reasons why a warfarin claim may not appear, enrollees were
excluded from the 6-month window if they experienced 1 of the following in the 6-month
calendar window: 1) hospitalization as determined through a claim in either the inpatient
services or inpatient admission files; 2) hepatic-related diagnosis (ICD-9: 570.0, 571.0,
571.2, 571.4, 571.5, 571.9, 572.2, 572.4, 573.3); 3) vitamin K deficiency (ICD-9: 269.0,
286.7); 4) antiphospholipid syndrome (ICD-9: 795.79); 4) other coagulation deficiency
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(ICD-9: 286.0, 286.1, 286.2, 286.3, 286.4, 286.5, 286.52, 286.53, 286.59, 286.6, 286.7,
286.8); 5) cardiac ablation procedure (CPT procedure code: 93650, 93651); 6) outpatient
prescription claims for either heparin or low-molecular weight heparin medications
(dalteparin, fondaparinux, enoxaparin, tinzaparin). These exclusions were captured as the
INR test may have been used diagnostically in these conditions without a concurrent
warfarin prescribing process or to assess the effects of recent warfarin use despite its
discontinuation.20 Patients with an inpatient admission were excluded because it was
unknown whether missing warfarin claims from a hospitalization might result in INR testing
in the outpatient setting. Otherwise, a missing warfarin claim could be misattributed. Use of
prescription aspirin was also identified in the outpatient drug files as aspirin could
potentially affect the use of anticoagulation and was used as an exclusion criterion in
sensitivity analyses.20
For each 6-month calendar period, demographic and insurance plan variables were also
identified including: age, region of residence, type of health benefit plan, and gender.
Medication Usage
Prescription drug use was identified through national drug codes (NDC) in the outpatient
drug files, merged with the REDBOOK supplement. The cohort assembled based on the
inclusion and exclusion criteria was merged with the outpatient drug files to identify those
enrollees with warfarin or branded warfarin medication (including Coumadin, Bristol-Myers
Squibb, Princeton NJ, and other branded generics not part of the four-dollar generic
programs: Jantoven, Marevan, Lawarin, or Waran) exposure at any point in the 6-month
calendar window, regardless of whether these occurred prior to or after the INR and AF
diagnosis dates. For each prescription claim filled for either generic or branded warfarin, the
patient out-of-pocket copay amounts were also captured. Use of aspirin (appearing in the
generic name) was also captured from the outpatient drug files.
Statistical Analyses
The proportion of enrollees with at least 1 appearing claim for a generic or branded
medication was calculated for each 6-month calendar window and calendar year. 95%
confidence intervals were calculated for each proportion of patients. Descriptive statistics
were calculated and assessed for all other variables. Chi-square (χ2) tests on the proportion
of patients with prescription exposure were conducted to compare the cross sections over
time. Multivariable generalized estimating equations were used to estimate the effect of the
low-cost generic programs on the adjusted relative proportion of patients with warfarin use
as a dependent variable. These models were adjusted for gender, age, region, and insurance
plan type, and standard errors were computed robustly using an exchangeable correlation
matrix to account for the within-patient correlation of outcomes. The baseline trend change
in the proportion of patients with warfarin prescriptions compared with the first 6-month
period (early 2003) and the level change following the low-cost generic programs were
estimated. The major low-cost generic programs began in early 2007, so the post-period for
the analysis was classified as the cross-sections beginning in 2007.21 Sensitivity analyses
were also conducted on the inclusion and exclusion criteria to examine how the restrictions
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affected the results. The association between demographic characteristics and the proportion
of patients with prescription exposure was also examined.
For those prescriptions that appeared within the calendar window periods, the day supply
and the average copayment for a 30-day supply was calculated for both generic and brand
medication per 6-month cross section. Of those prescriptions appearing, the proportion of
generic warfarin prescriptions filled for $4.00 per 30 day supply and $10.00 per 90 day
supply were also calculated. The proportion of generic prescriptions filled for $0.00 was also
captured, indicating that the fill was covered by the insurance. As a secondary analysis, the
percentage of mail order use over time per prescription was also assessed. The analyses on
medication costs and mail order source were performed to assess trends and possible
simultaneous changes in those prescriptions that do appear in the commercial claims
databases.
All analyses were performed using SAS 9.2 (SAS institute, Cary, North Carolina). Statistical
significance was determined as p<0.05. The UNC Institutional Review Board approved this
study.
RESULTS
Between 2003 and 2009, we identified 111,170 continuously-enrolled patients with
pharmacy insurance benefits having at least 2 outpatient AF diagnoses, 2 INRs, and 1
pharmacy claim within at least one 6-month period. In total, these individuals contributed to
264,206 6-month periods. When excluding patients for the potential concomitant
restrictions, including hospitalization, vitamin K deficiency, antiphospholipid syndrome or
other coagulation disorders, hepatic-related disorders, ablation procedure, or prescription
fills for heparin or low-molecular weight heparins, 80,267 patients remained, contributing to
183,308 6-month periods. In the cohort of 80,267 individuals, the demographic
characteristics and distributions per calendar year are displayed in Table 1. Individual plan
composition changed somewhat, with the database containing more individuals with
Preferred Provider Organization plans and fewer comprehensive or Health Maintenance
Organization plans over time.
We present the proportion of patients identified as having warfarin exposure overall and
across the 7 years in Table 2. Across all periods, the percentage of patients filling warfarin
was 89.4% (95% CI: 89.2-89.5). Trends for exposure completeness for both generic and
branded medication per 6-month calendar window are illustrated in Figure 1. Between 2003
and 2009, there was a significant decline in the percentage of patients with any warfarin
exposure, from 91.7% (95% CI: 91.0, 92.4) in early 2003 to 87.1% (95% CI: 86.7-87.6) in
late 2009 (χ2=93.8, p<0.0001). Over the same interval, the proportion of patients with
generic warfarin exposure appearing increased significantly (χ2=649.3, p<0.0001), while
the proportion of patients with branded warfarin exposure decreased significantly
(χ2=1,833.5, p<0.0001). Adjusting for demographic characteristics and within-patient
correlation, the multivariable models indicated that there was no significant trend between
the 6-month cross-sections at baseline (β=−0.0004, p=0.49) for patient exposure to any type
of warfarin. Adjusting for the baseline trend, a significant level change occurred in the post-
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period between 2006 and 2007 (β=−0.0058, p<0.0001) with an odds ratio of 0.994 (95% CI:
0.993-0.996). By comparison, there were significant trends between the 6-month cross-
sections at baseline for brand (β=−0.0211, p<0.0001) and generic (β=0.0188, p<0.0001)
warfarin, as illustrated in Figure 1. There were also significant level changes occurring for
the proportion of patients with generic warfarin (β=−0.0092, p<0.0001) exposure in the
post-period; no significant level change occurred for patients with brand warfarin
(β=0.0020, p=0.14) exposure in the post-period.
Considering that to be included in the cohort, each individual had to have a minimum of 2
INR tests in the 6-month window, the mean (standard deviation [SD]) frequency of INR
tests in each 6-month cross section varied from 6.17 (3.47) in early 2003 to 6.49 (3.59) in
late 2009. These frequencies were also the minimum and maximum number of INR tests per
individual recorded in any of the 14 6-month cross sections, suggesting little change in INR
testing frequency over time. The association between demographic characteristics and
proportion of patients with prescription exposure is displayed in Table 3.
In Table 4, we present results from the sensitivity analyses in which we reduced restrictions
on the exclusion criteria (e.g., antiphospholipid syndrome, coagulation deficiencies). The
proportion of patients with warfarin exposure appearing increased very slightly with the
restrictions. In addition, excluding those with prescription use of any aspirin products also
did not appreciably change the proportion of patients with warfarin exposure appearing.
Furthermore, additional sensitivity analyses restricting the same analyses to 3-month
calendar windows instead of 6-month windows did not change the proportion of patients
with warfarin exposure appearing over time.
Among generic and branded warfarin prescriptions appearing, the mean copayment per 30-
day supply of medication for generic medications decreased slightly over time from $4.93 in
early 2003 to $3.86 in late 2009. By comparison, the mean branded medication copayment
per 30-day supply remained fairly stable over time from $9.66 in early 2003 to $9.93 in late
2009. The mean (SD) day supply (e.g., 30 days) of medication dispensed per prescription
also were similar between generic (38.9 [23.2] days) and branded medications (37.4 [22.0]
days) in early 2003 and through late 2009 (42.5 [25.6] vs. 43.1 [25.7] days). The proportion
of generic warfarin prescriptions filled for $0.00, $4.00 per 30 day supply, and $10.00 per
90 day supply are displayed in the Appendix 1. Concurrently, use of mail order pharmacy
services for generic prescriptions also remained fairly stable over time, with 16.2% (95% CI:
14.6-17.9) of prescriptions delivered through mail order services in early 2003 compared
with 15.9% (95% CI: 15.1-16.7) of prescriptions in late 2009.
DISCUSSION
To address emerging concerns regarding completeness of pharmacy data in insurance claims
databases, our study sought to estimate the percentage of generic prescriptions that are
captured in commercial claims databases in the United States. Using a commercial claims
database, we estimated this quantity by examining generic warfarin prescribing among
patients receiving regular INR testing to manage warfarin dosing through a design that
enabled us to capture missing information because of a direct and specific monitoring test
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appearing in medical claims. Because there is little reason that regular INR tests would be
ordered on atrial fibrillation patients without concomitant warfarin use outside of the
exclusions applied,18-20 all patients in our cohort should have filled at least one prescription
for warfarin during our study period.
We found that about one in ten patients who received regular INR testing did not have an
associated warfarin claim. Our findings support the possibility that there exists a substantial
amount of prescription medication use that is not captured in pharmacy claims data, which
could be attributable to those filling outside the context of the pharmacy benefit for some
medications but not for others, such as through spousal benefits or dual eligibility for
multiple pharmacy benefit programs such as concomitant Veterans Affairs coverage.
However, it is possible that some of these patients may not be filling prescriptions despite
receiving specific testing to monitor medication dosing.3,4,22 Perhaps a strong desire to
please their providers, observed in other contexts,23,24 could lead them to agree to regular
INR testing, even though they are not taking the prescribed medication. This is probably not
a common occurrence but may account for some of the claims that appear to be missing.
In addition, our study showed a small increase in the percentage of patients not filling
warfarin over time, despite evidence of use as indicated by the presence of monitoring of
INRs. It was interesting to note a significant decline in the percentage trend of patients with
INR values matching to warfarin claims from 2007 to 2009 when generic discount programs
became commonplace in community pharmacy settings, as indicated by the multivariable
models. Missing data as a result of reduced prescription insurance billing has been noted as
a potential concern but not formally tested in other papers.6 This could be a result of the
introduction of the low-cost generic programs; however, other secular changes may be
responsive for this trend such as increasing use of mail order pharmacies, which may in turn
cause patients to circumnavigate their insurance benefit in the event of acute medication
changes to fill at traditional pharmacies.25,26 These secular trends were not sensitive to study
inclusion and exclusion criteria, indicating robustness of our results.
Our study was conservative by design. In the 6-month follow-up period, if a patient filled
any medication that was captured, the patient would be classified as having non-missing
data. It is possible that some of these patients may have had additional fills that were not
captured or the timing of the INRs in the cross sections may have separated the fills and
INRs over two different periods. However, as patients were not required to have remained
adherent or have multiple fills over the 6-month period, if patients were to have one missing
claim and one captured claim, they would be counted as having complete data. Therefore the
percentage of missing claims could be somewhat higher.
No matter what the cause, a moderate rate of missing prescription claims could have
important implications for research and quality improvement activities. In non-experimental
studies of the safety and effectiveness of prescription medications, missing claims may
cause exposure and covariates to be misclassified, leading to bias that may be difficult to
predict or diagnose.1 In particular, non-user groups may consist of some patients who are
treated and apparently new users may consist of patients who have previously treated. It is
reasonable to conduct sensitivity analyses to see how varying degrees of misclassification of
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exposure and covariate may bias results. It also may be possible to minimize this problem
through study design.
In studies of the appropriateness of prescribing, lack of complete pharmacy claims may
cause some patients to appear to be under-treated. In studies of medication adherence,
exposure misclassification could cause patients who are adherent to treatment, to appear to
be non-adherent.6 These biases could potentially affect appropriate targeting of quality
improvement activities designed to improve medication use.6 To reduce these problems,
researchers conducting studies using administrative claims should consider restricting to
those individuals using their pharmacy benefits and explore other approaches that can be
used to identify patients who are less likely to have missing data. Researchers should also
consider restricting or stratifying by generic and brand medication use to examine the
robustness of their results, especially in drug utilization and medication adherence studies.
Our study is limited by generalizability. Our database contains information on a wide variety
of commercially-insured patients in the United States; however, these results may not be
generalizable to other types of insurance databases, such as Medicare or Medicaid.27
Medicaid claims in particular may not suffer from this problem since the Medicaid co-
payment is required to be $3 or less in many states, thus incentivizing patients to provide
insurance information to the pharmacy or purchase medications through their pharmacy
benefit.26 On the other hand, we may not expect the same degree of completeness for other
medications, as patients on warfarin may be even less likely to shop around, particularly if
changing generics may lead to additional INR tests.20 For these other medications, we may
perhaps even expect a smaller degree of completeness in prescription claims, as patients
may be more likely to switch between pharmacies and potentially generic formulations.
CONCLUSION
The issue of completeness of pharmacy claims data is important for both research and
quality improvement activities. We find evidence of missing prescriptions among patients
being treated with warfarin for atrial fibrillation. Further investigation and monitoring is
required to better understand the magnitude and nature of this potential problem across
different databases and therapeutic areas.
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Proportion of generic warfarin copayment amounts in the cross-sections per year
(2003-2009)














$0.00 10.03 10.39 9.93 13.24 15.57 18.92 20.57
$4.00 per 30 day supply 1.03 1.22 0.22 0.89 3.96 8.20 8.80
$10.00 per 90 day supply 11.24 12.30 12.70 12.12 10.73 12.70 17.11
*
Number of total prescriptions for generic warfarin filled per year
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• Between 2003-2009, we estimated that 10.6% of commercially-insured patients
with atrial fibrillation had missing drug information for generic or branded
warfarin.
• From early 2003 to early 2009, the percent of commercially-insured patients
with atrial fibrillation with any warfarin exposure decreased from 91.7% (95%
CI: 91.0, 92.4) to 87.1% (95% CI: 86.7-87.6).
• Lack of complete pharmacy claims may impact medication adherence
assessments and other observational studies using commercial pharmaceutical
claims.
• Additional research is warranted across different databases and therapeutic
areas.
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Claims completeness for generic and branded warfarin in per total number of patients included in the 6-month cross-sectional
cohorts
Abbreviation: CI, Confidence interval
Lauffenburger et al. Page 12











































Lauffenburger et al. Page 13
TABLE 1
Demographic characteristics of the individuals
*
 in the cohort per year (2003-2009)














Age, mean (SD), y 57.2 (6.8) 56.8 (6.4) 56.8 (6.4) 56.7 (6.4) 57.0 (6.3) 56.8 (6.4) 57.0 (6.3)
Gender
    Male, No. (%) 5,708 (70.2) 7,957 (70.4) 10,388 (70.9) 10,405 (71.7) 11,117 (70.9) 18,376 (72.1) 18,919 (72.3)
Region (No., %)
    Northeast 1,292 (15.9) 1,222 (10.8) 1,620 (11.1) 1,783 (12.3) 1,762 (11.2) 4,123 (16.2) 3,399 (13.0)
    North Central 1,881 (23.1) 2,566 (22.7) 3,484 (23.8) 3,829 (26.4) 4,097 (26.1) 7,958 (31.2) 8,307 (31.8)
    South 2,886 (35.5) 4,636 (41.0) 6,111 (41.7) 6,347 (43.7) 6,905 (44.0) 9,688 (38.0) 10,474 (40.0)
    West 2,041 (25.1) 2,787 (24.7) 3,325 (22.7) 2,454 (16.9) 2,847 (18.2) 3,617 (14.2) 3,934 (15.0)
Plan (No., %)
    Comprehensive 1,403 (17.4) 1,528 (13.7) 1,550 (10.8) 1,335 (9.4) 680 (4.4) 1,320 (5.3) 961 (3.8)
    HMO 1,965 (24.3) 2,145 (19.2) 2,974 (20.6) 2,079 (14.7) 2,189 (14.3) 4,384 (17.6) 3,673 (14.4)
    POS 720 (8.9) 1,313 (11.8) 1,589 (11.0) 1,545 (10.9) 1,700 (11.1) 2,137 (8.6) 1,918 (7.5)
    PPO 3,655 (45.3) 5,731 (51.3) 7,784 (54.0) 8,648 (61.2) 10,145 (66.2) 16,179 (64.8) 17,972 (70.4)
Abbreviations: SD, Standard Deviation; HMO, Health Maintenance Organization; POS, Point of Service; PPO, Preferred Provider Organization
*
Characteristics are provided at the individual level per year, so column totals add to less than 183,308
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TABLE 2
Claims completeness for generic and branded warfarin for individuals in the yearly cohorts containing INR
claims
Year No. of 6-month cross









2003 12,472 60.6 (59.7-61.4) 37.2 (36.3-38.0) 91.6 (91.1-92.1)
2004 17,666 62.3 (61.5-63.0) 35.5 (34.8-36.2) 91.5 (91.1-91.9)
2005 23,173 68.4 (67.8-69.0) 30.2 (29.6-30.8) 91.1 (90.8-91.5)
2006 23,056 69.5 (68.9-70.1) 26.5 (25.9-27.0) 90.8 (90.5-91.2)
2007 24,552 71.3 (70.7-71.9) 22.4 (21.8-22.9) 89.5 (89.1-90.0)
2008 40,579 72.4 (71.9-72.8) 19.1 (18.7-19.5) 88.1 (87.8-88.4)
2009 41,810 74.7 (74.3-75.2) 15.1 (14.8-15.4) 87.2 (86.8-87.5)
Total 183,308 70.1 (69.9-70.4) 23.8 (23.4-24.2) 89.4 (89.2-89.5)
Abbreviations: INR: international normalized ratio; CI, Confidence interval
*
Columns may add up to more than the total
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TABLE 3
Association between demographic characteristics and proportion of warfarin prescriptions
*
 appearing in the
individuals
§
 in the cohort per year (2003-2009)















    ≥60 years 1.06 (0.91-1.24) 1.14 (1.00-1.29) 1.17 (1.04-1.31) 1.06 (0.95-1.19) 1.08 (0.98-1.19) 1.02 (0.94-1.10) 1.01 (0.94-1.09)
Gender (ref=male)
    Female 1.11 (0.95-1.31) 0.93 (0.81-1.07) 1.05 (0.93-1.18) 1.07 (0.95-1.21) 1.12 (1.01-1.25) 1.08 (1.00-1.17) 0.98 (0.90-1.06)
Region (ref=Northeast)
    North Central 1.00 (0.77-1.31) 1.73 (1.38-2.16) 1.38 (1.14-1.68) 1.36 (1.13-1.63) 1.09 (0.91-1.32) 1.93 (1.74-2.14) 1.05 (0.94-1.18)
    South 0.63 (0.50-0.80) 1.30 (1.07-1.58) 1.15 (0.97-1.37) 1.14 (0.96-1.35) 0.66 (0.56-0.78) 1.82 (1.64-2.01) 1.05 (0.94-1.17)
    West 0.95 (0.73-1.24) 1.53 (1.23-1.89) 1.19 (0.98-1.45) 1.15 (0.94-1.40) 0.93 (0.76-1.13) 1.85 (1.62-2.10) 1.13 (0.99-1.29)
Plan (ref=Comprehensive)
    HMO 1.21 (0.92-1.60) 0.75 (0.58-0.97) 0.71 (0.56-0.89) 0.97 (0.74-1.26) 1.17 (0.87-1.58) 0.62 (0.51-0.75) 1.00 (0.80-1.25)
    POS 0.96 (0.68-1.35) 0.71 (0.84-0.95) 0.73 (0.56-0.84) 0.83 (0.63-1.08) 1.05 (0.78-1.43) 1.01 (0.80-1.27) 0.88 (0.96-1.12)
    PPO 0.60 (0.48-0.75) 0.58 (0.47-0.73) 0.66 (0.53-0.81) 0.67 (0.54-0.84) 0.73 (0.56-0.95) 0.79 (0.65-0.95) 0.81 (0.66-0.99)
Abbreviations: OR, Odds Ratio; CI, Confidence Interval; HMO, Health Maintenance Organization; POS, Point of Service; PPO, Preferred Provider
Organization
*
Any warfarin prescription (generic or brand)
§
Characteristics are provided at the individual level per year, so column totals add to less than 183,308
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TABLE 4
Restrictions on claims completeness for generic and branded warfarin for individuals in the 6-month calendar













    No Exclusion Criteria 266,010 71.6 (71.4-71.8) 22.9 (22.6-23.3) 89.4 (89.2-89.5)
    ≥ 1 prescription fill 264,206 71.5 (71.3-71.7) 22.9 (22.6-23.3) 89.3 (89.2-89.4)
    Hospitalization 197,943 70.3 (70.1-70.6) 23.7 (23.3-24.1) 89.5 (89.3-89.6)
    Hepatic-related diagnosis 262,507 71.6 (71.4-71.8) 23.0 (22.6-23.3) 89.4 (89.2-89.5)
    Vitamin K deficiency 262,760 71.5 (71.3-71.7) 23.0 (22.6-23.3) 89.3 (89.2-89.4)
    Anti-phospholipid syndrome 263,821 71.5 (71.3-71.7) 22.9 (22.6-23.3) 89.3 (89.2-89.4)
    Other coagulation deficiency 255,628 71.4 (71.2-71.6) 23.0 (22.6-23.3) 89.2 (89.1-89.4)
    Cardiac ablation procedure 252,295 71.4 (71.2-71.6) 23.0 (22.7-23.4) 89.3 (89.1-89.4)
    Outpatient claim for either heparin or
LMWH
245,117 70.8 (70.6-71.0) 22.9 (22.6-23.3) 88.8 (88.6-88.9)
    All exclusion criteria 183,308 70.1 (69.9-70.4) 23.8 (23.4-24.2) 89.4 (89.2-89.5)
    All criteria + prescription aspirin use 182,989 70.1 (69.9-70.4) 23.8 (23.4-24.2) 89.4 (89.2-89.5)
Abbreviations: INR: international normalized ratio; CI, Confidence interval; LMWH: Low-molecular weight heparin
*
Columns may add up to more than the total
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